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Background: Cancer stem cells (CSCs) are considered the cell subpopulation responsible for breast cancer (BC)
initiation, growth, and relapse. CSCs are identified as self-renewing and tumor-initiating cells, conferring resistance
to chemo- and radio-therapy to several neoplasias. Nowadays, th (about 10mM)e pharmacological targeting of CSCs
is considered an ineludible therapeutic goal. The antidiabetic drug metformin was reported to suppress in vitro and
in vivo CSC survival in different tumors and, in particular, in BC preclinical models. However, few studies are available
on primary CSC cultures derived from human postsurgical BC samples, likely because of the limited amount of tissue
available after surgery. In this context, comparative oncology is acquiring a relevant role in cancer research, allowing
the analysis of larger samples from spontaneous pet tumors that represent optimal models for human cancer.
Methods: Isolation of primary canine mammary carcinoma (CMC) cells and enrichment in stem-like cell was carried
out from fresh tumor specimens by culturing cells in stem-permissive conditions. Phenotypic and functional
characterization of CMC-derived stem cells was performed in vitro, by assessment of self-renewal, long-lasting
proliferation, marker expression, and drug sensitivity, and in vivo, by tumorigenicity experiments. Corresponding
cultures of differentiated CMC cells were used as internal reference. Metformin efficacy on CMC stem cell viability
was analyzed both in vitro and in vivo.
Results: We identified a subpopulation of CMC cells showing human breast CSC features, including expression of
specific markers (i.e. CD44, CXCR4), growth as mammospheres, and tumor-initiation in mice. These cells show
resistance to doxorubicin but were highly sensitive to metformin in vitro. Finally, in vivo metformin administration
significantly impaired CMC growth in NOD-SCID mice, associated with a significant depletion of CSCs.
Conclusions: Similarly to the human counterpart, CMCs contain stem-like subpopulations representing, in a
comparative oncology context, a valuable translational model for human BC, and, in particular, to predict the
efficacy of antitumor drugs. Moreover, metformin represents a potential CSC-selective drug for BC, as effective
(neo-)adjuvant therapy to eradicate CSC in mammary carcinomas of humans and animals.
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Breast cancer (BC) is the most common and fatal malig-
nancy in women [1]. Accumulating evidence supports
the presence, within BC, of a subpopulation of tumor
cells, named cancer stem cells (CSCs). These cells ex-
hibit stem-like features, such as self-renewal, differenti-
ation capacity, and are believed to represent the
subpopulation responsible for the tumor-initiating activ-
ity and the resistance to antineoplastic agents [2,3]. In
vivo, CSCs sustain tumor growth, reproducing the het-
erogeneity of the original tumor from which they are de-
rived [4]. According to the current carcinogenesis
theory, BC development and recurrence is driven by
CSCs [5], and these cells represent the main pharmaco-
logical target for tumor eradication. Breast CSCs were
initially characterized from surgically removed human
tumors, although their isolation was possible only in a
small percentage of postsurgical specimens [6]. However,
since this first seminal study, most of the research on
breast CSCs was carried out in established cancer cell
lines [7,8], which were reported to contain putative CSC
subpopulations. Conversely, only few studies were per-
formed using cells isolated from tumor samples [9,10].
This limitation was likely a consequence of the CSC rar-
ity within the tumor mass and the usually extremely
small post-surgical specimens available for in vitro stud-
ies. A possible pitfall using cells expressing CSC signa-
tures but isolated from continuous BC cell lines, is that
they might include subsets of cells adapted to prolonged
in vitro culture in the presence of high serum concentra-
tion that, overtaking the majority of the tumorigenic
subpopulations, inadequately represent cancer cell het-
erogeneity. Moreover, due to genotypic and phenotypic
alterations, these cells often show different drug respon-
sivity from tumors in vivo [3,11].
The human BC cell subpopulation identified as CSCs
is characterized by CD44+/CD24low/− phenotype, the
ability to grow in vitro as mammospheres maintaining a
constant percentage of stem cells, high tumorigenicity
in vivo [6,9], developing serially transplantable tumors in
immunodeficient mice [12], indicative of long-term self-
renewal ability [13,14]. Moreover, several BC CSC features
are also relevant to metastasis, such as high motility, inva-
siveness, and resistance to apoptosis and drug treatments.
Recently, comparative oncology emerged as a relevant
tool for pharmacological development in human cancer
research. Spontaneous pet tumors represent important
pre-clinical models of human cancers retaining the het-
erogeneous nature of tumors and allowing the validation
of treatment strategies that will result beneficial to both
human and animal patients [15,16]. These tumors,
which develop in immunocompetent animals, at odd
with those experimentally induced in laboratory rodents,
display genetic, histopathological and biological featuressimilar to the human counterpart, as well as the meta-
static pattern and the response to therapy [17]. For ex-
ample, spontaneous canine mammary carcinomas
(CMCs) retain inter- and intra-tumor heterogeneity, as
human cancer [18-20] but, due to the shorter life-span
of dogs, they allow the evaluation of the natural course
of the tumor and its pharmacological modulation after a
shorter lag time than that required in human clinical
trials. Thus, CMC is considered a reliable comparative
model for human BC [21]. CMC is the most common
neoplasm of female dogs, representing 50-70% of all tu-
mors [22], and multiple deregulated genes and signaling
pathways (PI3K/AKT, KRAS, PTEN, Wnt-beta catenin,
MAPK, etc.) identified as responsible for its develop-
ment, nicely resemble those observed in humans [19].
For example, the expression level of epidermal growth
factor receptor (EGFR) in CMCs affects clinical progno-
sis [23]; HER-2 overexpression, occurring in about 20%
of CMCs as in BC [24], or the loss of estrogen (ER) and
progesterone (PR) receptors [25] are related to tumor
progression. Moreover, triple-negative CMCs (lacking
ER, PR and HER-2) show clinical-pathological character-
istics associated with unfavorable prognosis, similarly to
the triple-negative phenotype in women [26].
Because of the limited source of primary human BC tis-
sues due to early diagnosis and multiple histopathological
analysis required during and after surgery, and the lack of
in vivo preclinical models that accurately reflect patients’
tumor biology, the study of pet spontaneous tumors may
represent an innovative approach. However, this model is
still underused and, in particular, studies on the role of
CSCs in tumor development and treatment are lacking.
In veterinary research, putative CSCs have been identi-
fied in canine osteosarcoma, glioblastoma, acute myeloid
leukemia, hepatocellular carcinoma [27-31], as well as in
feline mammary carcinomas [32]. CSC-like subpopula-
tions were isolated and partially characterized from ca-
nine mammary cancer continuous cell lines [33-35],
mainly relying on in vitro observations, such as spheroid
formation, cell surface antigens and aldehyde dehydro-
genase (ALDH) activity, whereas isolation of CSCs from
spontaneous canine mammary tumors have been de-
scribed only in few studies [36]. Immunodetection of
cells with CD44+/CD24− phenotype in canine mammary
tumor tissues, similarly to human BC CSCs, has been
also reported [37], and CD44 expression has been asso-
ciated with proliferation of cultured canine cancer cells
[38]. Moreover, canine CSCs, isolated from the REM134
cell line, are resistant to common chemotherapeutic
drugs and radiation, exhibiting epithelial-mesenchymal
transition (EMT) phenotype [34].
Metformin is the first-line hypoglycemizing agent used
for the treatment of type 2 diabetes (T2D) due to its effi-
cacy and safety profile [39]. Epidemiological studies
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duced cancer incidence and mortality; furthermore met-
formin therapy seems to improve the clinical outcome
of diabetic patients with cancer and to exert a protective
anticancer effect in non-diabetic patients [40,41]. Thus
metformin’s antitumor properties are currently tested in
several clinical trials, mainly focusing on BC [42,43].
Preclinical in vivo studies reported that metformin re-
duces growth of BC xenografts in mice [44,45], and dir-
ectly inhibits the proliferation of several BC [46,47] and
other tumor [48] continuous cell lines, mainly interfering
with CSC proliferation. However, in all these studies the
effects of metformin, alone or in combination with doxo-
rubicin or trastuzumab, were mainly evaluated in CSC-
like derived from established lines [49-51].
Thus, the evidence of metformin activity in human BC
CSCs is still limited, and a comparative approach study-
ing CSCs from spontaneous dog tumors presents several
advantages, including the retention of intra-tumor cell
heterogeneity, an extremely relevant issue to identify
pharmacological approaches with higher predictive val-
idity when translated from preclinical to clinical setting.
Moreover, since these tumors are often not treated be-
fore surgery, comparative oncology provides the unique
opportunity in a preclinical model to map the nascent
BC biology, without modifications induced by therapy
pressure. Since CSCs are generally highly resistant to
chemotherapy, drugs that successfully target this sub-
population may represent an effective therapeutic ap-
proach, and the analysis of efficacy on CMC may pave
the way to the identification of clinically useful com-
pounds in humans.
The aim of this study was to establish cell cultures
enriched in CSCs from spontaneous CMCs, in order to
provide a cellular model that may better reflect BC het-
erogeneity, pathogenesis and drug responses. Moreover,
we tested the effects of metformin on CSCs isolated and
characterized from spontaneous CMCs, providing evi-
dence that these cells are highly responsive to in vitro
and in vivo metformin treatment.
Methods
Canine mammary carcinoma tissues
Sixteen CMC samples were collected after surgical re-
section from the local network of free-lance veterinary
practitioners (Genova, Italy), as described [32]. All histo-
pathological diagnoses were reviewed and assessed accord-
ing to the WHO International Histological Classification of
Mammary Tumors of the Dog and Cat [52], and tumor
grade was assigned [53].
Immunohistochemistry
Immunohistochemistry (IHC) was as described previ-
ously [54]. Antibodies used were as follows: anti-EGFR(rabbit polyclonal; Cell Signaling Technology), anti-ER-α
clone 1D5, anti-CD44, clone DF1485 and anti-Ki-67, clone
MIB-1, (mouse monoclonal, Dako, Glostrup, Denmark)
and anti-CD24 (goat polyclonal; SantaCruz Biothechnol-
ogy). All these antibodies are directed against human epi-
topes but cross-react with the canine counterpart, as
described [55-57]. Briefly, paraffin sections were deparaffi-
nized and rehydrated, antigen unmasking was performed
using citrate-antigen retrieval and Real Envision Detec-
tion System Peroxidase/DAB+, mouse/rabbit (Dako)
was used for the detection according to the manufac-
turer's instruction. Counterstaining with haematoxylin
concluded the processing. Images were captured using
a Nikon Coolscope microscope. For CD44, ER-α and
EGFR expression, both the intensity of immunoreaction
and the percentage of positive cells were evaluated, and
a score ranging from 0 to 3 was assigned (0 = negative,
1 = low positivity, 2 = positivity, 3 = high positivity). Ki-
67 labelling index (Ki-67 LI) was evaluated, using anti-
Ki-67 antibody, as the percentage of positive cell out of
at least 1,000 neoplastic cells (Ki-67 LI: 1 = <10%, 2 =
10-50%, 3= > 50%), in 10 randomly selected microscopic
fields. For each staining, a positive control was included
(human breast cancer tissues), as well as a negative
control, without the primary antibody or with rabbit/
mouse IgG. Mitotic index (MI), as an indirect measure
of cell proliferation, was evaluated as the number of mi-
totic figures per 10 high-power fields (HPF). Mitotic
figures were counted in areas selected on the basis of
the presence of good cellularity and high density of mi-
totic figures. Counting and semi-quantitative estimate of
percentage of positive cells of IHC was evaluated and in-
dependently scored by two pathologists (A.R. and C.C.).Cell cultures
After surgery, tumor tissues were immediately processed
for isolation of CSCs [32]. Tumor were finely minced and
incubated in trypsin/collagenase for 20 min with agitation
at 37°C, vigorously pipetted and cells passed through a
70 μm strainer (BD Biosciences, Milano, Italy) to obtain in-
dividual cells then plated in DMEM/Ham's F12 (1:1)
medium, penicillin/streptomycin (100 U/ml), and glutam-
ine 2 mM supplemented with 10% fetal bovine serum
(FBS) (all from Lonza, Milano, Italy) or in a stem-cell per-
missive medium: (DMEM/Ham's F12 (1:1) without FBS,
additioned with EGF (20 ng/ml), bFGF (10 ng/ml) both
from Milteny Biotec (Bologna, Italy), 0.4% BSA (w/v,
Sigma-Aldrich, Milano, Italy), and insulin (5 μg/ml, Sigma-
Aldrich) to ensure stemness maintenance [9,32]. To induce
differentiation, sphere colonies grown in stem-permissive
medium were collected, dissociated into single cells, and
shifted to complete FBS-containing medium (without
growth factors) and cultured for at least 2 weeks [58].
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To characterize CMC cells and visualize the expression
of specific markers, immunocytofluorescence (IF) was
performed [32]. Briefly, stem (mammospheres) and dif-
ferentiated cells grown on coverslips were fixed in 4%
paraformaldehyde, blocked in normal goat serum
(Sigma-Aldrich) and the following antibodies were ap-
plied for 1 h at r.t.: CD44 (Cell Signaling Technology,
Danvers, MA, USA), epidermal growth factor receptor
(EGFR, Cell Signaling Technology), ER-α and pan-
cytokeratin (pan-CK) (Dako). Secondary fluorescent
antibodies, Alexa 488- and Alexa 568-conjugated goat
rabbit/mouse-specific (Molecular Probes, Life Technolo-
gies, Monza, Italy), were added for 1 h at r.t. Nuclei were
counterstained with 4',6-diamidino-2-phenylindole (DAPI,
Sigma-Aldrich). Negative controls were included in the
experiments by omitting primary antibodies. Images were
captured by confocal laser scanning microscope (Bio-Rad
MRC 1024 ES).
MTT Assay
Cytotoxic effects were determined using the MTT [3-
(4,5-dimethylthizol-2-yl)-2,5-diphenyltetrazolium bromide]
(Sigma-Aldrich) reduction assay [59]. Briefly, viable cells
(3x105) were plated into 48-well plates and incubated over-
night prior to exposure to increasing concentrations of
metformin (0.1-100 mM) and DOX (0.01-5 μM) in the
presence or absence of verapamil (10 μM). Cells were incu-
bated with MTT solution 0.25 mg/ml for 2 h at 37°C,
medium was removed and stain was solubilized in DMSO;
absorbance was measured spectrophotometrically at
570 nm. Dose–response curves were generated and IC50
values were calculated using nonlinear regression curve fit
analysis by Graph Pad Prism 5.2 (GraphPad Software, San
Diego CA, USA).
Clonogenic assay
Stemness of CMC CSCs was tested measuring the
colony-forming ability of individual cultures [60]. Cells
were seeded in 96-well plates, at <1 alive cell/well con-
centration; medium was changed twice a week. Plating
accuracy was monitored under light transmitted micro-
scope to confirm the presence of a single cell/well and
exclude wells with dead or multiple cells. The number of
wells that contained colonies was scored weekly up to
4 weeks.
Doxorubicin uptake and intracellular distribution assay
The natural fluorescence of doxorubicin (DOX, Sigma-
Aldrich) allows it to be localized by fluorescence micros-
copy in vitro [61]. CMC cells were seeded in 35 mm
glass bottom dishes and allowed to growth o.n., then
cells were exposed to 1 μM DOX for 20 h, in the pres-
ence or absence of 10 μM verapamil (Sigma-Aldrich).Cells were washed to remove non-associated drug and
counterstained with the lipophilic membrane stain
Vybrant DiO cell-labeling solution (Molecular Probes,
Life Technologies, Monza, Italy). Images were captured
by a DM2500 microscope equipped with a DFC350FX
digital camera (Leica Microsystems, Wetzlar, Germany).
In vivo xenograft studies
Female non-obese diabetic severe combined immunode-
ficient (NOD-SCID) mice (6–8 weeks old; Charles River,
Calco MI, Italy) were used to evaluate tumorigenicity of
CMC cultures [32,60]. Animals, housed in pathogen-free
conditions, were handled in agreement with Italian regu-
lations for the protection of animals used for scientific
purposes and guidelines of the Ethical Committee for
Animal Experimentation of the IRCCS-AOU San
Martino-IST (Genova, Italy). Viable cells (4x105) were
collected by centrifugation, resuspended in matrigel (BD
Biosciences) and pseudo-orthotopically injected in the
subcutaneous fat pad. Mice were inspected weekly for
tumor appearance by visual observation and palpation,
thereafter were monitored for any discomfort and
weighed until sacrifice. Tumor tissues were collected
and dissociated to single cells as described above and
after spheroid formation, cells were re-injected into new
recipient mice to verify tumor-forming ability and in-
cidence. The remaining tumor, fixed in 10% buffered
formalin and embedded in paraffin was used for
hematoxylin and eosin (H&E) histological evaluation.
Treatments were started 7 days after inoculation of
cells, in mice randomly allocated to groups receiving
metformin or vehicle and continued for the next
6 months until the mice were killed. Metformin
hydrochloride (Sigma-Aldrich) was dissolved in drink-
ing water to attain the dosage of 360 mg/kg/die (see
dose justification in Discussion). The water was chan-
ged every other day and measured for water intake.
No toxicity signs were observed in the treated animals.
Excised tumors were weighed, and portions were cul-
tured or fixed for further studies.
Plasma metformin measurement by high-performance
liquid chromatography (HPLC)
Plasma concentrations of metformin in treated mice
were determined by validated HPLC assay [62]. Mice
blood samples (~0.3 ml) were taken under anesthesia by
retro-orbital sinus bleeding, collected into heparinized
tubes and centrifuged at 3000 x g. Metformin hydro-
chloride was used for calibration standards and as refer-
ence substance. Mouse plasma and standards were
extracted with acetonitrile (0.5 ml) and reconstituted
with water. An aliquot of each extracted sample (50 μl)
was injected onto a Kontron HPLC system (Kontron
Instruments, Munich, Germany), connected to an oven
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with a mobile phase consisting of 20 mM K2HPO4 and
acetonitrile (97:3 v/v) at a flow rate of 1 ml/min at 18°C.
The UV detector (Kontron Instruments) was set at
236 nm (ABS 0.1, RT 0.1); the run lasted for 10 min.
Results analysis was performed using the signal integra-
tion software KromaSystem 2000 (BIO-TEK Instru-
ments Milano, Italy). The calibration curves of peak
areas vs. concentrations of metformin were linear giv-
ing a correlation coefficient r2 = 0.999.
Statistical analysis
All quantitative data were collected from experiments
performed in triplicate, and expressed as mean ± s.e.m.
Statistical analyses were performed using t-test (unpaired,
two-tailed) or one-way ANOVA with Dunnett’s or Tukey’s
post-tests, using GraphPad Prism 5.2 (GraphPad soft-
ware). Differences were considered significant for p < 0.05.
Results
Clinical and histopathological characterization of CMCs
Sixteen mammary carcinomas from female dogs were
analyzed. Animal and tumor characteristics are reported
in Table 1. Fresh tissue samples were divided into twoTable 1 Clinical data and histopathology of canine
mammary carcinomas
Total n. 16
Mean Age 10 yrs. (range 6–14)
N. %
Breed Pure 9 56
Mixed 7 44
Sex F 14 88
FS 2 12





Grade II 5 32
III 11 68





Histology: CT, carcinoma-simple, tubular; CTP, carcinoma-simple, tubulopapillary;
CSP, carcinoma-simple, papillary; CC, carcinoma complex; CA, carcinoma, anaplastic.
Sex: F: female, unspayed; FS: female, spayed.
Localization: M2, caudal thoracic; M3, cranial abdominal; M4, caudal abdominal;
M5, inguinal.
n.a.: not available.parts: one was immediately fixed in 10% formalin and
embedded in paraffin for histological diagnosis, and the
other was dissociated to obtain primary cultures. Histo-
logical diagnoses (Table 1) included 7 simple, 7 complex
and 2 anaplastic carcinomas. Tumor grade, highly pre-
dictive of epithelial tumors outcome in both dogs and in
humans, was assessed by the presence or absence of tu-
bule formation, nuclear pleomorphism, and the number
of mitosis per 10 HPF, and revealed 5 grade II and 11
grade III tumors. Notably, histopathological features of
this series of CMCs covered a wide range of representa-
tive canine tumor subtypes and pathological/prognostic
signatures that overlap most common human BC pro-
files. IHC was performed in all cases to evaluate the ex-
pression levels of the proliferation marker Ki-67, and to
identify CD44-expressing cells, as potential CSCs. To fur-
ther characterize tumor phenotype relevant receptors in-
volved in mammary tumorigenesis, such as ER-α and
EGFR, were analysed. Representative IHC images are
shown in Figure 1a. Tumor immunoreactivity for these
markers was assessed by semiquantitative IHC score, as
described in Materials & Methods (Figure 1 b). Ki-67 ex-
pression was classified as “low” in ~60% of tumors, while
about 10% were categorized as “intermediate” (range 10-
50% of positive cells). The analysis of the expression pat-
tern of EGFR showed a marked immunopositivity, al-
though detectable at different levels (46% score 1, and
33% score 2 or 3) in all tumors, while ER-α was detected in
a limited number of samples (about 25%). Interestingly, in
agreement with previous studies [63], CMCs showed differ-
ent ER-α localization, being either clearly nuclear or mainly
localized in the cytosol (Additional file 1: Figure S1).
CD44 expression, a potential CSC marker, as deter-
mined in human BC CSC (phenotype CD44+/CD24-/low),
was detected in scattered cells (score 1) in the 31% of
the cases, or in limited tumor regions (score 2) in 15%,
while 54% of tumors were negative. However, as previ-
ously reported [32], CD44 is likely underestimated by
random IHC sampling, due to the non-homogeneous ex-
pression within tissues, the predicted rarity of these
cells, their potential localization in stem cell niches and
the lack of analysis of serial sections of the samples. The
expression of CD24 was checked in our series of CMC
tissues but no stained cells were detected, accordingly to
previous observations [32,37].
Isolation and in vitro expansion of cancer stem-like cells
from CMC specimens
Primary CMC cultures were obtained from fresh tumors
by mechanical disaggregation and enzymatic digestion.
Single-cell suspensions, obtained by cell strainer filtra-
tion, were plated in stem-permissive culture medium
(serum-free and supplemented with bFGF and EGF). In
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Figure 1 Immunohistochemical expression of Ki-67, EGFR, ER-α and CD44 in canine mammary carcinomas. a) Representative staining of a
simple tubulopapillary carcinoma, analyzed for the expression of Ki-67 (nuclear staining), EGFR (both nuclear and cytoplasmic immunopositivity),
ER-α (distinct nuclear staining) and CD44 (cytoplasmic staining). Antibody localization was done using HRP, with dark brown staining indicating
the presence of the specific antigen. Original magnification 40X. Lower panels: negative controls (Neg.) obtained by using mouse (m) or rabbit (r)
IgG as primary antibody. b) Distribution of Ki-67 labelling index (LI; 1 = <10%, 2 = 10-50%, 3= > 50% of positive cells/total tumor cells) and IHC
scores (0 = negative; 1 = weak positivity; 2 = moderate positivity; 3 = strong positivity) for EGFR, ER-α and CD44 among CMC tissues.
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logically, CMC mammospheres, formed by cobblestone-
like epithelial cells, exhibited features of both floating
spheroids of variable sizes and partially attached irregu-
lar aggregates (Figure 2a, upper panels). In parallel, ali-
quots of primary culture from the same tumors, were
grown in DMEM-F12 supplemented with 10% FBS,
without growth factors. These culture conditions do not
allow the selection for CSC-like, favoring the prolifera-
tion of non-tumorigenic differentiated mammary carcin-
oma cells. In these conditions, cells grow in vitro as
adherent monolayers, showing a predominance of
spindle-like morphology, but are not able to generate
mammospheres (data not shown). CSC-like differenti-
ation ability was tested by shifting mammosphere-
derived cells in serum-containing medium (10% FBS,
devoid of growth factors) for at least 2 weeks. In these
conditions, cells from disaggregated spheroids adhered
to the substrate and acquired a spindle-like morphology,
resembling primary CMC cultures originally grown inFBS-containing medium, immediately after isolation
(Figure 2a, lower panels). To assess the pattern of prolif-
eration in vitro of CMC cells from both culture condi-
tions, growth-curves were generated according to the
absorbance values, in MTT assays. Proliferative activity of
cells in stem-permissive medium was markedly enhanced
when compared with differentiated cells, whose growth
rate reached a plateau stage early after seeding (Figure 2b).Phenotypic characteristics of canine mammary carcinoma
cells cultured in stem-permissive medium
To verify whether primary CMC cultures grown in stem
cell-permissive medium are indeed enriched in CSCs, we
characterized the phenotype of these cells by IF (Figure 2c,
upper panels). All stem-like cultures exhibited pan-
cytokeratin expression, consistent with their epithelial
origin. As self-renewal of human and animal mammary
cancer stem cells involves a diverse network of regulatory











Figure 2 Morphological appearance, proliferation and phenotyiping of CMC cultures. a) Morphological changes of floating mammospheres/
clusters in stem cell-permissive medium (upper panels) from a cobblestone-like morphology to spindle-like cells in adherent monolayers (lower panels),
after differentiation for 15 days in serum-containing medium. Phase-contrast images, original magnification 10X. b) Representative growth curves of
CMC cells selected under stem cell-permissive or differentiation medium, showing the in vitro proliferative potential of cultures. Arbitrary units (a.u.) are
referred to the number of living cells at day 1. Data represent the mean ± s.e.m. c) Enrichment in CD44+ cells and marker expression profile of CMC cells
grown in stem cell-permissive or differentiation medium. Immunofluorescence analysis of pan-cytokeratin (Pan-CK), EGFR, ER-α, CXCR4 and CD44 in
CMC spheroids (upper panels) and after 15-day exposure to serum-containing medium. Images from confocal microscopy, original magnification 100X.
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these proteins are expressed in CMC cultures.
We observed a marked positivity for EGFR within
spheres and single cells growing under stem-permissive/
serum-free conditions indicating that EGFR immunoposi-
tivity observed in tissue sections was retained after CSC
enrichment in vitro. CXCR4 was also expressed in CSC
cultures showing predominant membrane localization.
Conversely, the expression of ER-α was not detected in all
the cells of the analyzed spheroids, and 30% of them were
completely negative, in agreement with IHC analysis (see
Figure 1). Importantly, the expression of CD44, previously
reported as signature of human breast CSCs [6], was de-
tected in all cultures, providing evidence for enrichment
in stem-like cells and validating their identification in cor-
responding CMC tissues (Figure 2c). Differentiated cells
(shifted to serum-containing medium) conserved similar
expression profiles of all the markers, with the remarkable
exception of CD44, which was undetectable after differen-
tiation (Figure 2c).
CMC stem cells are tumorigenic in vivo
At present, the gold standard assay to assess CSC poten-
tial is the transplantation of prospectively identified can-
cer cell subpopulations into immunodeficient mice toassess tumorigenicity, phenocopying the original tumor
[64]. Mammosphere-derived CMC stem-like cells (4x105
cells/mouse), isolated from a grade III tubular carcin-
oma, were pseudo-orthotopically injected in NOD/SCID
mice. Tumor development was daily monitored, and ani-
mals were sacrificed after 23 weeks, when symptoms of
physical or behavioral deficits developed, due to tumor
size. Transplanted CMC cells achieved high take rate
(up to 100%) after first injections in mice (Figure 3a).
Cells derived from tumor explants, cultured again in
stem cell-permissive medium, grew as partially attached
aggregates or floating spheroids, as described for cul-
tures derived for CSC-like cells from the original tumor
(Figure 3b), retaining the tumor-initiating ability after
2nd injection into new recipient mice, efficiently generat-
ing secondary tumors (Figure 3a). However, when
shifted in FBS-containing medium these cultures ex-
hibited differentiated morphology and monolayer
growth (Figure 3b). Histopathological analysis of ori-
ginal and mouse xenograft tumors revealed that CSC-
like derived tumors closely reproduced the histotype of
the original CMC (i.e. carcinoma predominantly orga-
nized in tubular structures) (Figure 3c, left panels), in-
cluding CD44 expression in scattered tumor cells
evaluated by IHC (Figure 3c, right panels). Similar
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Figure 3 Tumorigenicity of stem-like cells derived from CMC cultures. a) Tumor-forming rates of mammosphere-derived cells from CMCs.
Cells were pseudo-orthotopically injected into NOD/SCID mice, and tumor development was monitored. Tumor take rate was 100% after the 1st injection.
Tumorigenicity rate was steadily up to 100% when cells recovered from primary xenografts were cultured in stem-permissive conditions and re-injected
into mice fat pads. b) Cells derived from mice xenografts appearance after in vitro culture. As the original cultures derived from canine carcinomas, cells
grow as partially attached or floating spheroids in stem conditions, while upon differentiation are able to attach to the substrate and grow as monolayer.
Phase-contrast images, original magnification 20X. c) Canine mammary stem-like cells fully recapitulate the tumor of origin when transplanted
into immunodeficient mouse. Histopathologic examination of implanted tumors: representative H&E staining reveals the typical appearance of
tubulopapillary carcinomas both in the original canine tumor and the corresponding mice xenograft; immunohistochemical staining for CD44
shows the presence of rare, but observed in each tumor tissue, positive cancer cells (original magnification 40X).
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tubulopapillary carcinoma or complex carcinoma (data
not shown).Collectively these data confirm the tumor-initiating
capacity of isolated CMC CSCs, and their ability to re-
capitulate the phenotype of the original tumor in vivo.
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the resistance by verapamil
Human BCs develop numerous mechanisms of resistance
to chemotherapeutic drugs, allowing them to survive con-
ventional therapies and to drive tumor recurrence and
metastasis. CSCs are believed to represent the main
source of drug-resistant cells [2].
To investigate whether these mechanisms are func-
tional in CMC stem cells, we monitored cell viability in
3 different CMC CSC cultures exposed to doxorubicin
(DOX, 0.01-5 μM), a standard drug for human BC. CSCs
were resistant to DOX (after 48 h no reduction of cell
viability was observed even at the highest concentration
tested, Figure 4a). Conversely, differentiated cells showed
high responsivity with maximal cell viability reduction
(−80% vs. untreated cells) observed after 48 h, and a
mean IC50 of 0.38 μM (Figure 4a and d). Comparison of
dose–response curves obtained from differentiated and
stem-like cells showed a highly significant statistical dif-












Figure 4 CMC stem cells are resistant to doxorubicin: reversal by vera
effects of doxorubicin (DOX) on cell viability, measured by MTT assays, in C
carcinoma (CMC) cells. A statistically significant reduction in cell viability of
higher concentrations vs. control), while CMC CSC were not affected. Data
CSC untreated (left) or treated (right) with the calcium channel blocker ver
lipid green dye DiO to highlight cell shape. Subcellular DOX fluorescence (
DiO, yellow) of resistant cells, while the fluorescent accumulation of DOX in
20X. c) Dose–response analysis of verapamil on the cytotoxic activity of DO
0.1 μM (*p < 0.05, **p < 0.01; ***p < 0.001 vs. respective value of DOX alon
using nonlinear regression curve fit analysis in CMC cells exposed to DOX aOne of the most common mechanism of resistance to
DOX, representing also a key feature of CSC subpopula-
tion, is the overexpression of ATP-binding cassette
transporters (ABCB1, ABCG2, and ABCC1) whose activ-
ity leads to cell extrusion of cytotoxic drugs.
To gain further insights into the role of ABC pumps
in drug resistance, we assessed the intracellular distribution
of DOX autofluorescence in CMC CSCs. We expected that
high activity of multidrug resistance transporters would
change the pattern of DOX localization and, specifically,
decrease its nuclear accumulation. As shown in Figure 4b,
after 24 h of treatment, DOX either was extruded from the
majority of the CSCs or, when entered cells, it was pumped
out from the nucleus accumulating in perinuclear/cyto-
plasmic structures, as evidenced by the merge of vital cell
dye DiO (green) and DOX (red) fluorescences, resulting in
colocalization (yellow) (Figure 4b, left panel). Inhibition
of ABCB1 pump function, by the calcium antagonist
verapamil (10 μM), prevented DOX exclusion, resulting




CSC + verapamil 0.45
CSC 
DOX                           DOX + verapamil
pamil pretreatment. a) Cumulative dose–response curves of the
SC (CMC CSC) and differentiated (CMC DIFF) canine mammary
CMC DIFF was observed (*p < 0.05 for 0.1 μM DOX, ***p < 0.001 for
represent the mean ± s.e.m. b) DOX intracellular distribution in CMC
apamil, to inhibit ABC transporter activity. CSCs were labelled with the
red) localization is mainly confined to cytoplasm (co-localization with
the nuclei is markedly increased by verapamil. Original magnification
X: reversal of resistance was significantly achieved starting from
e). Data represent the mean ± s.e.m. d) Mean IC50 values calculated
lone or in combination with verapamil.
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served in DOX-sensitive differentiated cells (data not
shown). These results, suggesting ABCB1 involvement in
CSC DOX resistance likely due to reduced access to nu-
clear targets, were confirmed by MTT experiments. CMC
CSCs treated with DOX plus verapamil for 48 h acquired
a significant responsivity to the cytotoxic drug (p = 0.025
vs. DOX alone, ANOVA) (Figure 4c), reaching a mean
IC50 of 0.45 μM, a value that was almost superimposable
to that observed in differentiated CMC cells (Figure 4d).
Verapamil had no significant effects on the subcellular dis-
tribution or accumulation of DOX in differentiated cells
that however showed a nuclear localization of the drug
also in the absence of verapamil (data not shown).
Metformin inhibits CMC stem-like cell viability in vitro
While CSCs are resistant to most conventional cytotoxic
drugs, recent data suggested their possible sensitivity to
drugs such as metformin [65,66]. To delve deeper in this
issue, we evaluated the effects of metformin in all the 16
CMC cultures. Metformin caused a significant reduction
of cell viability (p < 0.001, ANOVA), in a dose-dependent
manner, starting from the concentration of 1 mM, after
48 h of treatment, and reaching a mean IC50 of 12.59 ±
3.49 mM (range 0.40-31.22 mM) (Figure 5a). This effect
was mainly cytostatic up to the concentration of 10 mM
since, in cell growth recovery experiments, a significant
proliferation was observed, after drug wash-out, in cells
pretreated for 24 h and 48 h with metformin (p = 0.007
and p = 0.0004, respectively; Figure 5b). However, using
higher concentrations (20 mM) growth recovery was min-
imal after 24 h of treatment, and completely abolished
after 48 h, indicating a cytotoxic activity (Figure 5b).
Differentiated cell cultures were obtained in parallel
with stem-like cells from 13/16 tumors. Differently from
what reported in BC cell lines in which metformin was
highly selective for the CSC component [49], metformin
also affected viability of CMC cells grown in FBS-
containing medium, at concentrations higher than
10 mM (Figure 5c), showing a higher mean IC50 value,
but not statistically different from that obtained in the
CSCs isolated from the same tumors (24.5 mM vs.
17.8 mM). However, comparing viability curves of both
culture conditions, we found that CSCs display a signifi-
cantly higher reduction of viability than differentiated
cultures at all the tested concentrations, with the excep-
tion of the lowest one (0.1μM; Figure 5c), suggesting
that metformin actually targets with higher efficacy
CSC-like cells, while doxorubicin more efficiently blocks
differentiated cell proliferation.
Metformin impairs the growth of CMC stem-like cell in vivo
In order to directly test the in vivo effects of metformin
on CMC growth, metformin was orally administered indrinking water to 6 NOD-SCID mice xenografted with
CSCs (4x105) isolated from 1 tubular and 1 tubulopa-
pillary carcinoma (three mice per histotype), while
other 6 mice, injected with CSCs from the same tumors
(3 each), were used as untreated controls. Tumors were
allowed to grow till animals presented signs of physical
distress, when the mice were sacrificed. None of the an-
imals exhibited signs of drug-related toxicity. After
6 months, all mice were sacrificed, tumors explanted,
weighed, and divided in two samples, one analyzed by
IHC and the other dispersed to single cells cultured
in vitro. Metformin plasma concentrations were measured
in all treated mice, showing a mean level of 6.9 μg/ml
(range of 4.5-13.32), corresponding to ~41 μM a value
compatible with therapeutically efficacious concentration
in humans. Metformin caused a significant reduction of
tumor growth (−62% of tumor weight, p = 0.026 vs. un-
treated controls; Figure 6a). Xenografts morphologically re-
sembled the tumor of origin, but H&E staining highlighted
the presence of large necrotic areas in metformin-treated
tumors that were absent or extremely small, in control
tumors (Figure 6b). Importantly, a lower content of CD44-
expressing cells was observed in metformin-treated xeno-
grafts than in untreated tumors (Figure 6b), although a
precise quantification was not possible due to the hetero-
geneous presence of these cells within the tumor mass (see
also comments to data reported in Figure 1). Conversely,
the proliferative activity, assayed by quantification of Ki-
67-LI, confirmed a highly statistically significant reduction
in metformin-treated tumor sections as compared with
controls (Figure 6c). Mitotic index, a measure of cell prolif-
eration considered a strong predictor of the clinical out-
come for several human and canine cancers, also revealed
a significant decrease after metformin administration
(Figure 6c).
Finally, to define the impact of in vivo metformin
treatment on CSC viability, we analyzed the clonogenic
activity of individual CMC cells in ex vivo experiments,
as a CSC-based in vitro index of in vivo tumorigenicity.
Cells, derived from treated and control tumors, grown
in stem-permissive medium, were plated as single cells
and allowed to give origin to clones for up to 30 days.
About 13% of the cells derived from untreated tumors
retained clonogenic activity, a percentage compatible
with the CSC levels within the tumor mass, while only
2% of the cells from metformin-treated xenografts
retained this stem-defining feature. These data clearly
suggest that in vivo metformin treatment powerfully
affect the survival of CSCs. In addition, we observed that
CMC cultures derived from untreated and chronically
metformin-treated xenografts, grown in stem cell-
permissive conditions, were similarly sensitive to the an-
tiproliferative activity of metformin (IC50, 22 and










Figure 5 Metformin inhibits CMC stem cell viability in vitro. a) Dose–response of metformin on cell viability, measured by MTT assays, in
CMC CSC cultures. A statistically significant reduction in cell viability was observed (**p < 0.01 for 1 mM metformin and ***p < 0.001 for higher
concentrations vs. control). Data represent the mean ± s.e.m. b) Cell growth recovery assay in CSCs treated with metformin (10 and 20 mM) for
24-48 h and followed by drug withdrawal and growth in drug-free medium (medium change: MC) for further 24-48 h. Results from MTT assays
show cytostatic and cytotoxic effects of 10 mM and 20 mM metformin, respectively (**p < 0.01, ***p < 0.001 vs. corresponding treated cultures).
c) Box and whiskers plot of metformin effects on viability of CSC and differentiated (Diff) CMC cultures: boxes extend from the 25th to the 75th
percentile, lines indicate the median, whiskers extend to minimum and maximum data points. A significantly higher sensitivity of CSC cultures than
corresponding differentiated cells is evident stating from 1 mM metformin for 48 h (*p < 0.05; ***p < 0.001 vs. corresponding differentiated cells).
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evidence that desensitization of the antiproliferative
mechanisms activated by metformin does not arise dur-
ing prolonged in vivo treatment.
Discussion
The hierarchical model of carcinogenesis implies that
only a small subset of tumor cells, named CSCs ortumor-initiating cells, drives tumor development and
progression, determining drug responsiveness. Con-
versely, differentiated tumor cells, incapable of long-
term self-renewal but representing the majority of the
cells within hematologic and solid cancers, are not
tumorigenic. Although most studies addressing this issue
relied on established cancer cell lines rather than pri-






















































Figure 6 Metformin inhibits canine mammary CSC proliferation in vivo. a) Metformin significantly suppresses CMC CSC tumor growth. The
box-plot whiskers extend from the lowest to the highest tumor weight value, from tumors explanted from control or metformin-treated mice. A
significant statistical difference between the two groups is reported within the graph. b) Histopathological analysis of control and metformin-
treated excised xenografts. Representative images of mouse-developed canine mammary tubular carcinoma analyzed by histopathological and
immunohistochemical staining. H&E (upper panels, 20X) shows larger areas of necrotic tissue in treated tumors than in xenografts derived from
untreated mice (4X). Cells expressing CD44 and Ki-67 are evidenced by immunohistochemistry in lower panels (40X). c) Metformin reduces the
proliferative potential of mammary carcinoma cells within tumor: microscopic examination and quantification of Ki-67 and mitotic counts were
significantly reduced by metformin. d) Metformin significantly decreased clonogenicity of xenograft-derived cells surviving long-term metformin
exposure in vivo (*p<0.05).
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powerful and systematic in vitro isolation and in vivo
transplant of CSCs derived from fresh tumor tissues [64].
In the present study, we isolated and characterized CSCs
from CMC surgical tissues, by selection of primary CMC
cultures in stem cell permissive, serum-free medium for
several passages in vitro. CMC-derived stem cell-like
spheroids express CD44, as well as other BC related pro-
teins, such as EGFR and CXCR4, and showed high resist-
ance to DOX when compared to the corresponding CMC
differentiated cells. Xenografts in NOD/SCID mice dem-
onstrated that CMC CSCs derived from mammosphere
disaggregation, successfully initiate tumor formation.Breast cancer remains a major clinical challenge with
high mortality both in humans and companion animals
[1,25]. Advancement in understanding tumor biology
and public awareness campaigns led, in most cases, to
early BC diagnosis and neo-adjuvant treatments were
developed in women. While the better clinical manage-
ment significantly improved the overall prognosis of BC
patients, only small fragments of fresh tissues, frequently
already exposed to intensive cytotoxic therapy, are avail-
able from excised human tumors for experimental
purposes, also because large amounts are required for
intra- and post-surgery histopathological analyses. On
these premises, a major strength of our study is the use
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terial necessary to isolate mammary CSCs. Indeed, to
improve the knowledge of in vitro and in vivo biological
features of CSCs and their drug responses, allowing the
translation of preclinical findings into effective human
clinical trials, cell models that faithfully mimic BC cell
heterogeneity are an absolute requirement. Spontaneous
tumors of companion animals, such as CMC, are rather
frequent in the clinical veterinary practice [22] and thus
may provide a unique opportunity as a model for human
cancer translational research [15]. In contrast to experi-
mental tumor models in mice, CMCs develop naturally,
reproducing the same environmental and genetic aeti-
ology as occurs in humans, grow in immunocompetent
organisms [67] and share strong clinical (e.g. hormonal
dependence, age of onset, histological appearance, prog-
nostic factors, course of the disease) and molecular (e.g.
tumor genetics, overexpression of steroid receptors, pro-
liferation markers, EGF, p53 mutations, metalloprotein-
ases, cyclooxygenases) similarities to human BC [20,22].
Additionally, human and canine mammary tumors
show similar responses to conventional anticancer
agents and, more importantly, both display inter/intra-
patient tumor cell heterogeneity [68]. The enrichment in
CSCs has been largely demonstrated in established hu-
man and canine mammary cancer cell lines [5]. Here, we
reinforce the hypothesis of the stem cell basis for mam-
mary tumors, achieving isolation of such a population
from surgical samples. Features of CSCs include: (i) self-
renewal capacity, (ii) stem marker expression, (iii) ability
to reproduce the original tumor after xenografting, and
(iv) chemo-resistance. Therefore, we verified these pre-
requisites in CSCs derived from CMCs. Cell surface
marker CD44 [6], and the expression of the enzyme al-
dehyde dehydrogenase (ALDH), partially overlapping
within this subpopulation [69], were assumed as criteria
for CSC-enrichment and stem signatures in human BC,
correlating to the tumor-initiating ability. However, it is
currently debated whether these markers univocally
identify CSCs in all BCs [70,71]. Breast CSC plasticity
induced by tumor microenvironment, which allows these
cells to undergo reversible EMT, may influence distinct
marker profiles [72]. Nevertheless, CD44 was identified
as major target using CD44 antibodies [73] or inducing
CD44 down-regulation [74,75], to inhibit CSC prolifera-
tion and migration and overcome drug resistance.
In dogs, limited studies on mammary CSCs are avail-
able, thus their phenotyping is mainly derived from
commonly employed human markers [33,36], reprodu-
cing similar controversies: spheres from primary tumors
show the expression of CD49f (integrin α6) and CD29
[36] while spheres derived from canine cell lines express
CD44 and CD133 and/or Sox2 and Oct4 [33]. Moreover,
CD44 was associated to proliferative activity of culturedcanine cancer cells [38,71]. CMC cultures, analysed after
in vitro enrichment in stem-like cells, display CD44 ex-
pression in a high number of cells, while, in the tumor
of origin, CD44+ cells are confined in randomly spotted
tissue areas, as described for human samples [71],
explaining, as previously discussed, the apparent high
percentage of CD44 negative tumors. However, although
this is a non-defining criterion for CSC identification
[76] and we did not select CMC CSCs on the basis of
markers’ expression, we observed a depletion/decrease
of CD44+ cells upon CMC CSC differentiation (shifting
cell cultures in serum-containing medium), confirming
that this marker labels some CSC-like populations in
culture. In addition, we analysed the expression of genes
associated, in human and pet mammary cancers, with
stem/progenitor cell survival, self-renewal and tumor ag-
gressiveness, such as EGFR, ER-α and CXCR4 [54,77,78].
Similarly to the original tumors, CMC mammospheres
quite homogenously express EGFR confirming its rele-
vance in mammary cancer biology, and CXCR4, whose
signalling regulates BC stem cell activities and metastatic
potential [54,79]. Conversely, ER-α positivity was less
commonly detected in isolated CMC stem-like cells and
in tumor sections. The pattern of expression of these pro-
teins did not change in the corresponding differentiated
CMC cultures, showing that both the bulk of CMC cells
and CSC-enriched cultures retain in vitro the same dis-
tinctive factors, as master regulators of tumor formation
and growth. Thus, CSC cultures isolated from CMCs re-
produce the tissue heterogeneity, covering different histo-
pathological types and maintaining in culture the
phenotype observed in vivo.
CSC biomarker expression [80] and the ability to
growth in serum-free medium as non-adherent spher-
oids [81] are variably identified features in human and
canine mammary tumors, reflecting intra- and inter-
tumor heterogeneity but do not systematically define
CSCs [82]. Thus, functional validation, by means of
in vivo tumorigenicity experiments, is actually the more
reliable tool to corroborate the definition of cell popula-
tions as CSCs (tumor-initiating cells). We demonstrate
that CSCs isolated from CMC retain tumor-initiating ac-
tivity, by serial transplantation in NOD-SCID mice
(CSCs were xenografted, recovered and re-transplanted
to form new tumors in new recipient mice) achieving
about 100% of take rate after both 1st and 2nd injection,
reforming the heterogeneous population of CMC cells
within the xenografts. Another biological property gen-
erally ascribed to CSCs is drug resistance, as they more
efficiently survive therapy than differentiated cancer
cells. Indeed, the major challenge in BC treatment is the
targeting of CSCs usually refractory to conventional
drugs both in humans and in dogs [34]. This underlines
the need of novel preclinical models to test drug effects
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and DNA repair ability, and resistance to apoptosis, that
contribute to drug resistance. In fact, using these mecha-
nisms CSCs survive therapies contributing to recurrence
and progression, after the initial remission caused by the
differentiated tumor cell death [83]. Drug-resistance of
CMC CSCs is therefore similar to that observed in hu-
man BC stem cells, whose content within the tumor
mass is increased by chemotherapy [83], and in CSCs
isolated from a CMC cell line [34]. Therefore, although
cytotoxic treatments reduce the bulk of the tumor, they
may not affect the most important target: the CSCs. In
this study we developed a preclinical model reproducing
this in vivo condition. CMC CSCs survived DOX treat-
ment, at odd of differentiated cultures isolated from the
same tumors, likely due to transporters that pump out
the drug from the nuclei or outside the cells.
The need of drugs effectively targeting CSCs inspired
new approaches for anti-cancer drug discovery and in
particular the so-called “drug repositioning”. It was re-
ported that the biguanide metformin specifically inhibits
self-renewal and proliferation of CSC from several tu-
mors [66,84,85], including BC [49,51,86,87]. Starting
from early evidence using different biguanides [88-90],
the antitumor potential of metformin is now well-
established [65,91]. Epidemiological studies showed that
diabetic cancer patients may benefit of metformin
treatment and, on these bases, several clinical trials are
ongoing [92]. Recently, the inhibition of chloride intra-
cellular channel 1 (CLIC1) activity was identified as a
specific molecular mechanism by which metformin af-
fects only CSC viability, sparing normal stem cells [93],
making this molecule particularly interesting as novel
anticancer drug. We show that canine CSCs are not
sensitive to DOX cytotoxicity, but highly responsive to
metformin in vitro, while differentiated tumor cells are
only partially affected by metformin, although highly
responsive to DOX. These data confirm that combined
treatment with metformin and conventional cytotoxic
drugs may provide a therapeutic advantage. In fact,
while metformin is clearly preferentially active on
CSCs, a successful therapy will require targeting of
both undifferentiated CSCs and differentiated non-
CSCs [94], since the reverse transition of non-CSCs
into CSC subpopulation was also reported [95]. Mean
metformin IC50 values obtained in our experiments is
about 10 mM, ranging from 0.40 to 31 mM in cells
from different tumors, evidencing significant variability
in metformin activity among individual dog-derived
cells, as expected for the inter-patient tumor hetero-
geneity, although we remark that viability of CSCs from
all 13 CMCs analyzed was impaired. These IC50 values
are in line, and in some cases lower, with those of most
of the previous studies reporting antitumor activity ofmetformin (range 1–30 mM) [44,87,96,97]. However,
metformin concentrations used in vitro, exceeding
those achieved in vivo in T2D patients (10–30 μM
range) [39], are still a debating issue, due to the con-
cern whether these in vitro data might be relevant for
translation to clinics [98]. We acknowledge that the
concentrations used are higher than metformin steady
state plasma levels in T2D patients, however, the dis-
crepancy between clinical and in vitro conditions could
be less significant considering the following factors: (a)
metformin concentrations in tissues are several-fold
higher than those in blood because of tissue accumula-
tion [99], thus actual intra-tumor concentrations
should compare with in vitro results; (b) medium sup-
plements, required to maintain tumor cell proliferation
in culture (i.e. high concentrations of glutamine and glu-
cose), reduce cell sensitivity to metformin [4,100,101]; (c)
tumors often show increased cationic transporters com-
pared their normal counterparts [91] further favoring tissue
accumulation, (d) longer exposure of cell cultures to met-
formin (15–18 days) shift metformin-antitumor effect to a
lower threshold [44]. In fact, it was reported that in human
glioblastoma CSCs, short-term experiments (24-72 h, as
here reported) show metformin anti-proliferative activity in
the mM range [44,93,102], but increasing drug exposure to
15 days metformin efficacy was evident already at 10 μM
concentration [93]. This latter point might justify higher
IC50 in in vitro studies, supporting time-dependent mecha-
nisms that significantly differ between in vitro and in vivo
experimental conditions. This hypothesis was indeed sup-
ported by our demonstration that prolonged metformin
treatment of CMC xenografts resulted in reduced tumor
size and growth arrest and depletion of CSC content, for
much lower blood concentrations (about 40 μM) than re-
quired in vitro (about 10mM). The plasma levels ob-
tained treating mice with metformin dissolved in
drinking water to attain the dosage of 360 mg/kg body
weight/day, which is comparable to therapeutic doses
used for T2D as translated to humans (human equiva-
lent dose [103]: corresponding to ~1,750 mg/day in
an average-sized person of 60 kg), are therefore lower
than the maximum recommended dose in humans
(http://www.fda.gov/ohrms/dockets/dailys/02/May02/
053102/800471e6.pdf ).
Thus, in vivo dosing that induces a highly signifi-
cant reduction of tumor growth is within human
therapeutic range, even if the high safety profile and
negligible side-effects of metformin could allow ex-
perimental doses over pharmacological concentra-
tions. In very recent phase II and III clinical trials,
non-diabetic women with BC received metformin at
high dose (2 g/day) as adjuvant therapy [43,92], dem-
onstrating that higher blood concentrations can be
safely achieved.
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potential of cells surviving long-term in vivo exposure to
metformin, was markedly reduced as compared to un-
treated controls, indirectly confirming that metformin
preferentially kills CSCs. Moreover, desensitization in-
duced by prolonged exposure to metformin does not
occur in CMC CSCs after prolonged in vivo treatment,
since metformin still exhibits a strong and consistent an-
tiproliferative action in vitro on cells derived ex vivo
from both treated and untreated mice tumors. Above
observations support metformin as an attractive agent
for chemoprevention and use of low-dose for long period
in combination with cytotoxic agents like DOX to kill
both CSCs and the bulk of differentiated cancer cells.
Conclusions
CSC-like subpopulation can be isolated from spontan-
eous canine mammary carcinomas, strongly highlighting
the relevance of the comparative oncology model. Our
data support CMC stem-like cells as a powerful model
to provide information closer-to-primary cellular models
for the identification of novel CSC targeting agents and
the definition of biological behavior of stem-like cells in
human BC. The demonstration of significant antitumor
efficacy of metformin acting on CSC proliferative poten-
tial, along with the well-known safety profile support the
ongoing evaluation of metformin in the clinical neo-
adjuvant setting, although additional studies evaluating
metformin effects in conjunction with standard treat-
ments are needed to further focus the potential clinical
benefits of this drug in BC. Companion animals could
be investigated for possible translation to veterinary and
human medicine, which may strengthen the use of nat-
urally occurring CMC in dogs in comparative oncology
trials.
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